Home Page ::  Site Map  ::  Contact  
 

  Email Printable Version  

 
 

By Alphabetical Order

By Therapeutic Category

Advanced Search

 
 
 

AMINOPHYLLINE (Adults)

- Aminophylline 400 mg

- Pharmaceutical form: suppositories

- Therapeutic category: Bronchodilator

 

 

Composition and Presentation:

Aminophylline rectal supp, Children, 6 supp. / box or 10 supp. / Box.
Each rectal suppository contains: Aminophylline 400 mg.

 

Properties:

Aminophylline is a xanthene bronchodilator has diuretic properties.

 

Pharmokineticks:

Aminophylline, a complex of theophylline with ethylenediamine, readily liberates theophylline in the body. Rectal absorption may be slow. Approximately 40 % is bound to plasma proteins. Theophylline is metabolized in the liver, these metabolites are excreted in the urine. In adult, about 10 % of the dose is excreted unchanged in the urine. It crosses the placenta, also enters breast milk.

 

Indications:

Aminophylline is used similarly as bronchodilator in the management of asthma and chronic obstructive pulmonary disease. It was formerly used in the treatment of heart failure, for its diuretic properties.

 

Contraindications:

Aminophylline is contra-indicated in patients with shown hypersensitivity to any component of this product.

 

Side Effects:

Aminophylline may cause nausea, vomiting, abdominal pain, headache, cardiac arrhythmias and tachycardia.

 

Drugs and Interaction:

Theophylline interacts with a wide variety of drugs: cimetidine, disulfiram, macrolide antibiotics and quinolones, phenytoin, diazepam, beta2-adrenoceptor stimulants, corticosteroids and diuretics.

 

Warnings:

Aminophylline should be given with caution to:
- Patients with peptic ulceration, hyperthyroidism, cardiac or liver disease.
- Neonate, elderly, pregnant woman and nursing mothers.

 

Dosage:

Dosage must be determined individually and according to the physician's instructions.
Adult: 1 suppository daily at bedtime.

 

Storage:

Store at room temperature below 30ú C.

 

Home

Profile Drugs News Articles Site map Contact us